TransCode Therapeutics Begins Phase 1 Clinical Trial

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology company dedicated to improving cancer treatment through RNA therapeutics, has initiated its Phase 1 multicenter, open-label clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial locations have already been activated, and patient enrollment is slated to commence this quarter. TransCode aims to activate up to five trial sites within the same timeframe.

The Phase 1 clinical trial aims to gather pivotal data to assess the safety of TTX-MC138 in patients suffering from various metastatic solid cancers. The trial also has the potential to provide early indications of TTX-MC138's clinical activity. It will start with a dose-escalation phase, followed by a dose-expansion phase. The primary goal of the dose-escalation phase is to evaluate the safety and tolerability of increasing doses of TTX-MC138. In the subsequent dose-expansion phase, the safety, tolerability, and anti-tumor activity of TTX-MC138 will be further examined in specific tumor types, chosen based on preliminary results from the dose-escalation phase.

"We are excited about the substantial interest in TTX-MC138 from leading oncologists at some of the nation's most respected clinical trial sites," said Sue Duggan, Senior Vice President of Operations at TransCode. Duggan emphasized that advancing RNA therapeutic science in clinical settings is their main objective, leveraging innovative technology.

TransCode Therapeutics is a clinical-stage oncology company that focuses on treating metastatic disease. The company is dedicated to conquering cancer through the intelligent design and effective delivery of RNA therapeutics, utilizing its proprietary TTX nanoparticle platform. TTX-MC138, the company's leading therapeutic candidate, aims to treat metastatic tumors that overexpress microRNA-10b, a unique and well-documented biomarker of metastasis. Additionally, TransCode is developing a range of first-in-class RNA therapeutic candidates to overcome RNA delivery challenges, thereby unlocking therapeutic access to various genetic targets that could be relevant for treating multiple types of cancer. 

TransCode's approach involves a portfolio of RNA therapeutics designed to address the hurdles of RNA delivery effectively. Their lead candidate, TTX-MC138, targets microRNA-10b, a biomarker closely associated with metastasis in cancers. This focus could provide new avenues for treating metastatic cancers more effectively.

The enthusiasm from the oncological community for TTX-MC138 underscores the potential impact of this innovative treatment. With clinical sites ready and patient enrollment imminent, TransCode is making significant strides toward its goal of revolutionizing cancer treatment through RNA therapeutics. The Phase 1 trial will be crucial in determining the future applications and efficacy of TTX-MC138, potentially offering a new hope for patients with metastatic solid tumors. 

This advancement is a testament to TransCode's commitment to pioneering RNA-based solutions in oncology, aiming to bring novel and more effective treatments to the forefront of cancer care. The ongoing research and trials will likely shape future therapeutic strategies, offering a beacon of hope for combating metastatic cancer more effectively.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!